Mouse Anti-BICD2 Recombinant Antibody (CBYY-0559) (CBMAB-0562-YY)

Name: Mouse Anti-BICD2 Recombinant Antibody (CBYY-0559)
SKU: CBMAB-0562-YY
Rating: 5 (1 reviews)

See all BICD2 antibodies

Compare Online Inquiry

Datasheet

SDS

Request for COA

Datasheet Target References Q & As Review & reward Protocols Associated Products

Basic Information

Host Animal

Mouse

Clone

CBYY-0559

Application

WB, IP, IF, ELISA, IHC-P

Immunogen

Amino acids 154-173 near the N-terminus of BICD2 of human origin.

Host Species

Mouse

Specificity

Human, Mouse, Rat, Horse, Pig

Antibody Isotype

IgG2b, κ

Clonality

Monoclonal

Application Notes

The COA includes recommended starting dilutions, optimal dilutions should be determined by the end user.

Application	Note
WB	1:100-1:1,000
IP	1-2 µg per 100-500 µg of total protein (1 ml of cell lysate)
IF(ICC)	1:50-1:500
ELISA	1:100-1:1,000
IHC-P	1:50-1:500

Formulations & Storage [For reference only, actual COA shall prevail!]

Format

Liquid

Buffer

PBS, 0.1% gelatin

Preservative

< 0.1% sodium azide

Concentration

0.2 mg/ml

Storage

Store at +4°C short term (1-2 weeks). Aliquot and store at -20°C long term. Avoid repeated freeze/thaw cycles.

More Infomation

Target

Full Name

BICD Cargo Adaptor 2

Introduction

This gene is one of two human homologs of Drosophila bicaudal-D and a member of the Bicoid family. It has been implicated in dynein-mediated, minus end-directed motility along microtubules. It has also been reported to be a phosphorylation target of NIMA related kinase 8. Two alternative splice variants have been described.

Entrez Gene ID

Human	23299
Mouse	76895
Rat	306809

UniProt ID

Human	Q8TD16
Mouse	Q921C5
Rat	Q712J3

Alternative Names

BICD Cargo Adaptor 2; Bic-D 2; Cytoskeleton-Like Bicaudal D Protein Homolog 2; Bicaudal D Homolog 2 (Drosophila); Homolog Of Drosophila Bicaudal D; Protein Bicaudal D Homolog 2;

Function

Acts as an adapter protein linking the dynein motor complex to various cargos and converts dynein from a non-processive to a highly processive motor in the presence of dynactin. Facilitates and stabilizes the interaction between dynein and dynactin and activates dynein processivity (the ability to move along a microtubule for a long distance without falling off the track) (By similarity).
Facilitates the binding of RAB6A to the Golgi by stabilizing its GTP-bound form. Regulates coat complex coatomer protein I (COPI)-independent Golgi-endoplasmic reticulum transport via its interaction with RAB6A and recruitment of the dynein-dynactin motor complex (PubMed:25962623).
Contributes to nuclear and centrosomal positioning prior to mitotic entry through regulation of both dynein and kinesin-1. During G2 phase of the cell cycle, associates with RANBP2 at the nuclear pores and recruits dynein and dynactin to the nuclear envelope to ensure proper positioning of the nucleus relative to centrosomes prior to the onset of mitosis (By similarity).

Biological Process

Centrosome localization Source: UniProtKB
Microtubule anchoring at microtubule organizing center Source: BHF-UCL
Microtubule-based movement Source: GO_Central
Minus-end-directed organelle transport along microtubule Source: BHF-UCL
mRNA transport Source: UniProtKB-KW
Protein localization to Golgi apparatus Source: UniProtKB
Protein localization to organelle Source: GO_Central
Protein transport Source: UniProtKB-KW
Regulation of microtubule cytoskeleton organization Source: ARUK-UCL
Retrograde vesicle-mediated transport, Golgi to endoplasmic reticulum Source: UniProtKB

Cellular Location

Golgi apparatus; Cytoskeleton; Cytoplasm; Nucleus envelope; Nuclear pore complex. In interphase cells mainly localizes to the Golgi complex and colocalizes with dynactin at microtubule plus ends (By similarity). Localizes to the nuclear envelope and cytoplasmic stacks of nuclear pore complex known as annulate lamellae in a RANBP2-dependent manner during G2 phase of the cell cycle (PubMed:20386726).

Involvement in disease

Spinal muscular atrophy, lower extremity-predominant 2A, childhood onset, autosomal dominant (SMALED2A): An autosomal dominant form of spinal muscular atrophy characterized by early-childhood onset of muscle weakness and atrophy predominantly affecting the proximal and distal muscles of the lower extremity, although some patients may show upper extremity involvement. The disorder results in delayed walking, waddling gait, difficulty walking, and loss of distal reflexes. Some patients may have foot deformities or hyperlordosis, and some show mild upper motor signs, such as spasticity. Sensation, bulbar function, and cognitive function are preserved. The disorder shows very slow progression throughout life.
Spinal muscular atrophy, lower extremity-predominant, 2B, prenatal onset, autosomal dominant (SMALED2B): An autosomal dominant neuromuscular disorder characterized by decreased fetal movements, fractures in utero, severe congenital joint contractures, arthrogryposis multiplex congenita, severe hypotonia, muscle atrophy, and respiratory insufficiency and failure due to muscle weakness. Some patients may have dysmorphic facial features and/or abnormalities on brain imaging. Death in early childhood may occur.

PTM

Phosphorylated by NEK9 in vitro.

Marchionni, E., Agolini, E., Mastromoro, G., Guadagnolo, D., Coppola, G., Roggini, M., ... & Pizzuti, A. (2021). Fetal early motor neuron disruption and prenatal molecular diagnosis in a severe BICD2‐opathy. American Journal of Medical Genetics Part A, 185(5), 1509-1514.

Vallee, R. B., Yi, J., Quintremil, S., & Khobrekar, N. (2021). Roles of the Multivalent Dynein Adaptors BicD2 and RILP in Neurons. Neuroscience Letters, 135796.

Tumurkhuu, M., Batbuyan, U., Yuzawa, S., Munkhsaikhan, Y., Batmunkh, G., & Nishimura, W. (2021). A novel BICD2 mutation of a patient with Spinal Muscular Atrophy Lower Extremity Predominant 2. Intractable & Rare Diseases Research, 10(2), 102-108.

Gonçalves, J. C., Quintremil, S., Yi, J., & Vallee, R. B. (2020). Nesprin-2 recruitment of BicD2 to the nuclear envelope controls dynein/kinesin-mediated neuronal migration in vivo. Current Biology, 30(16), 3116-3129.

Storbeck, M., Eriksen, B. H., Unger, A., Hölker, I., Aukrust, I., Martínez-Carrera, L. A., ... & Wirth, B. (2017). Phenotypic extremes of BICD2-opathies: from lethal, congenital muscular atrophy with arthrogryposis to asymptomatic with subclinical features. European Journal of Human Genetics, 25(9), 1040-1048.

Ask a question We look forward to hearing from you.

0 reviews or Q&As

Purchasing FAQs
Technical FAQs

Have you used Mouse Anti-BICD2 Recombinant Antibody (CBYY-0559)?
Submit a review and get a Coupon or an Amazon gift card. 20% off Coupon

$30 eGift Card
Submit a review

Please try the standard protocols which include: protocols, troubleshooting and guide.

Enzyme-linked Immunosorbent Assay (ELISA)
Flow Cytometry
Immunofluorescence (IF)
Immunohistochemistry (IHC)
Immunoprecipitation (IP)
Western Blot (WB)
Enzyme Linked Immunospot (ELISpot)
Proteogenomic
Other Protocols

Related Products

Mouse Anti-BICD2 Recombinant Antibody (CBYY-0558) (CAT#: CBMAB-0561-YY)

Mouse Anti-BICD2 Recombinant Antibody (CBYY-0560) (CAT#: CBMAB-0563-YY)

Isotype control

For research use only. Not intended for any clinical use.

Custom Antibody Labeling

We also offer labeled antibodies developed using our catalog antibody products and nonfluorescent conjugates (HRP, AP, Biotin, etc.) or fluorescent conjugates (Alexa Fluor, FITC, TRITC, Rhodamine, Texas Red, R-PE, APC, Qdot Probes, Pacific Dyes, etc.).

Online Inquiry

Request bulk or custom quote Second antibody and isotype control

Contact us

Tel: (USA)
(UK)
Fax:

Global Locations

Email:

Online Inquiry